gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Pancreatic Cancer and Cancer of Unknown Primary (CUP)

Meeting Abstract (OP119)

RNAi-based knockdown of bcl-2 sensitises pancreatic cancer to gemcitabine treatment

Ocker M, Neureiter D, Sass G, Hahn EG, Herold C
Meeting Abstract (OP120)

Adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer - a randomised, prospective, multicenter phase III study (CONKO-001)

Oettle H, Roll L, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, Zülke C, Ziske J, Burkart C, Niedergethman M, Fahlke J, Langrehr J, Riess H
Meeting Abstract (OP121)

Prognostische Relevanz der Lymphgefäßdichte im Pankreaskarzinom

Kleespies A, Assmann G, Wilkowski R, Löhrs U, Diebold J, Jauch KW, Bruns C
Meeting Abstract (OP122)

Lymph Node Status and Prognosis of Malignant Endocrine Pancreatic Tumors after Curative Surgical Resection

Demir R, Meyer T, Merkel S, Hohenberger W
Meeting Abstract (OP123)

Poly (ADP-ribose)polymerase inhibitor 3-aminobenzamide in combination with gemcitabine shows strong antitumor activity in pancreatic cancer cells

Jacob D, Bahra M, Langrehr J, Neuhaus P, Neumann U
Meeting Abstract (OP124)

5-lipoxygenase is a new key player and tumor promoter in pancreatic carcinogenesis

Hennig R, Esposito I, Grippo P, Rao SM, Giese N, Büchler MW, Friess H, Bell RH, Adrian TE
Meeting Abstract (OP125)

A randomized, prospective phase III second line trial of patiens with gemcitabine resistant advanced pancreatic cancer (CONKO 003).

Pelzer U, Roll L, Stieler J, Hilbig A, Schwaner I, Adler M, Seraphin J, Dörken B, Riess H, Oettle H
Meeting Abstract (PO126)

Effects of inducible p53 reconstitution in an orthotopic mouse model of pancreatic cancer

Otto N, Schulz P, Scholz A, Rexin A, Hauff P, Schirner M, Wiedenmann B, Detjen K, Rosewicz S
Meeting Abstract (PO127)

Phase II Study of First Line Sorafenib (BAY 43-9006) in Patients with Locally Advanced and/or Metastatic Pancreatic Cancer – a Study of the Central European Society for Anticancer Drug Research - EWIV (CESAR)

Scheulen ME, Mross K, Dittrich C, Hochhaus A, Morant R, Köberle D, Krauß J, Frost A, Flashar C, Edler L, Scheuring U, Strumberg D
Meeting Abstract (PO128)

Matuzumab (EMD 72000) und Gemcitabine im tierexperimentellen Pankreaskarzinom

Kleespies A, Mantell O, Amendt C, Yezhelyev M, Guba M, Jauch KW, Bruns C
Meeting Abstract (PO129)

Zoledronic Acid has Direct anti-Proliferative and anti-Metastatic Effect on Pancreatic Carcinoma Cells and Acts an Antigen for γ2 γ/δ T cells

Märten A, von Lilienfeld-Toal M, Büchler M, Jäger D, Schmidt J
Meeting Abstract (PO130)

Immunomonitoring of the CapRI Trial: First Results

Märten A, Jäger D, Büchler M, Schmidt J
Meeting Abstract (PO131)

Sonic Hedgehog(SHH) in pancreatic cancer: Effect of the small molecule inhibitor Hh-Antag

Bahra M, Koch A, Langrehr JM, Hartmann W, Schüller U, Schulz N, Neuhaus P, Pietsch T
Meeting Abstract (PO132)

Nuclear DNA content and survival rates of patients with pancreatic cancer: a prospective study on 64 cases

Seehofer D, Al-Abadi H, Langrehr J, Weidemann H, Bahra M, Abou-Rebyh H, Veltzke-Schlieker, W, Neuhaus P
Meeting Abstract (PO133)

Severe Hypocalcaemia During Therapy With Low-Dose Cisplatin, 5-Fluorouracil And Interferon alpha

Hoffmann K, Lindel K, Fritz S, Maerten A, Jaeger D, Buechler M, Schmidt J
Meeting Abstract (PO134)

Locally Advanced Pancreatic Cancer - can combined Chemo-/Radiotherapy prolong Survival? Single-Center Experience on Mitomycin/Fluorouracil-based Chemo-/Radiotherapy

Grothaus-Pinke B, Rohn R, Heike M
Meeting Abstract (PO135)

A randomized, prospective, multicenter, phase III trial of gemcitabin (g), 5-fluorouracil (5-fu), folinic acid (fa) vs. gemcitabine alone in patients with advanced pancreatic cancer (CONKO 002)

Pelzer U, Helm A, Niedergehtmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Köhler K, Stauch M, Riess H, Oettle H
Meeting Abstract (PO136)

A Prospective, Randomized trial Of Simultaneous Pancreatic cancer treatment with Enoxaparin and ChemoTherapy (PROSPECT – CONKO 004)

Pelzer U, Hilbig A, Stieler J, Roll L, Stauch M, Opitz B, Scholten T, Zippel K, Hahnfeld S, Dörken B, Riess H, Oettle H
Meeting Abstract (PO137)

Treatment of patients with advanced pancreatic cancer using gemcitabine, cisplatin, 5-fluorouracil, folinic acid (GFFC) and concomitant low-molecular weight heparin (enoxaparin) in an outpatient setting: a pilot study

Hilbig A, Pelzer U, Stieler J, Roll L, Bernd D, Riess H, Oettle H
Meeting Abstract (PO138)

Phase III Trial CapRI (adjuvant ChemoRadioImmunotherapy of pancreatic adenocarcinoma) versus 5-FU alone

Märten A, Schmidt J, Märten A, Jäger D, Büchler M
Meeting Abstract (PO139)

Report on recruiting in a centre for the trial "Preoperative chemoradiotherapy in locally resectable adenocarcinoma of the pancreatic head without metastasis”

Golcher H, Meyer T, Brunner T, Baum U, Böhner C, Papadopoulos T, Grabenbauer G, Hohenberger W